Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 2 Compliance with collection times by study stage

From: The longitudinal impact of low-dose morphine on diurnal cortisol profiles in people with chronic breathlessness and chronic obstructive pulmonary disease (COPD): an exploratory study

  

n

(expected number of samples = n x 6)

Collection compliance and quality

n (row %)

  

Within 1 h of designated time

Within 3 h of designated time

No time recorded**

Missing sample

Study stage

Baseline

20 (120)*

83 (69.2)

4 (3.3)

33 (27.5)

-

Stage 1

End of week 1

17 (102)

55 (53.9)

3 (2.9)

39 (38.2)

5 (4.9)

Stage 3

End of week 3

11 (66)

63 (95.5)

3 (4.5)

-

-

Stage 4

End of 3 months

7 (42)

35 (83.3)

1 (2.4)

6 (14.3)

-

  1. *placebo n = 6; sustained release morphine 8 mg n = 8; sustained release morphine 16 mg n = 6
  2. ** There was no statistical difference between compliant and non-compliant sub-groups at any study stage for diurnal cortisol slope nor AUCg
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us